Scientific article

Anticoagulation orale et pharmacogénétique : perspectives pour la pratique clinique

Published inRevue médicale suisse, vol. 3, no. 124, p. 2030-2036
Publication date2007

Single nucleotide polymorphisms (SNPs) in genes encoding cytochrome P450 enzyme 2C9 (CYP2C9) and Vitamin K epoxide reductase subunit I (VKORC1) make a significant contribution to the inter-individual variability in the maintenance dose of vitamin K antagonists (warfarin, acenocoumarol, phenprocoumon). Doses requirements in CYP2C9*2 and CYP2C9*3 heterozygotes are reduced by 8-16% and 20-36%, respectively. SNP g-1639a in VKORC1 is also associated with vitamin K antagonists dosage since heterozygotes ga and homozygotes aa require respectively 21-28% and 27-56% less warfarin or acenocoumarol than homozygotes gg. CYP2C9 and VKORC1 account for up to half the variability in vitamin K antagonists requirements and incorporating genotying data for these two genes into dosing algorithms could lead to a safer anticoagulation therapy.

  • Anticoagulants/pharmacology
  • Aryl Hydrocarbon Hydroxylases/genetics
  • Cytochrome P-450 CYP2C9
  • Humans
  • Mixed Function Oxygenases/genetics
  • Pharmacogenetics
  • Polymorphism, Single Nucleotide
  • Vitamin K/antagonists & inhibitors
  • Vitamin K Epoxide Reductases
Citation (ISO format)
BENUSIGLIO, Patrick Raphaël et al. Anticoagulation orale et pharmacogénétique : perspectives pour la pratique clinique. In: Revue médicale suisse, 2007, vol. 3, n° 124, p. 2030–2036.
ISSN of the journal1660-9379

Technical informations

Creation11/03/2016 10:09:00 AM
First validation11/03/2016 10:09:00 AM
Update time03/15/2023 1:07:14 AM
Status update03/15/2023 1:07:14 AM
Last indexation01/16/2024 10:39:25 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack